Bipolar Disorder (Manic Depression) Market Summary
The total diagnosed prevalent cases of Bipolar Disorder (Manic Depression) in the 7MM were approximately 3,552,076 in 2020, and the therapeutic market is expected to grow positively during the study period (2017–2030). This change is mainly due to the increase in prevalence and the launch of upcoming therapies during the forecast period. The US had the largest number of diagnosed prevalent cases of Bipolar Disorder (Manic Depression) in 2020, at 2,401,287 cases, compared to EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Antipsychotics have emerged as the cornerstone of pharmacologic therapy for patients with Bipolar Disorder (Manic Depression), providing significant benefits in terms of mood stabilization, symptom improvement, and quality of life. Currently approved therapies in the 7MM include Vraylar (cariprazine) and Latuda (lurasidone hydrochloride), among others. Emerging therapies are focusing on different mechanisms, such as lumateperone (serotonin-dopamine-glutamate modulator), NRX-100/NRX-101 (sequential NMDA-targeted therapy), SEP-4199 (serotonin 5-HT7/dopamine D2 modulator), and brexpiprazole (partial dopamine D2 agonist), among others.
Explore DelveInsight’s Full Coverage on the Bipolar Disorder (Manic Depression) Market
Bipolar Disorder (Manic Depression) Overview
Bipolar disorder (BD), previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes – BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS) – with classification based on the characteristics of mood swings.
Bipolar Disorder (Manic Depression) is a lifelong condition that creates unusual mood changes that can vary in length and severity. For people living with Bipolar Disorder (Manic Depression), there are three times as many depressive episodes as manic ones, and those episodes often last 50% longer. The symptoms include feeling sad or anxious, restlessness, trouble concentrating or making decisions, sleep disturbances, lack of interest, feelings of hopelessness or worthlessness, thinking about death or suicide, inability to perform even simple tasks, and talking very slowly or forgetting frequently.
Unlock in-depth Bipolar Disorder (Manic Depression) epidemiology data and comprehensive market forecast analysis
Bipolar Disorder (Manic Depression) Diagnosis and Treatment Algorithm
Bipolar Disorder (Manic Depression) is often misdiagnosed as unipolar depression as long as manic episodes do not appear. The diagnosis usually requires a physical examination, psychiatric assessment, mood charting, and the use of ICD-10 or DSM-5 criteria for bipolar episodes. There is no specific test available for diagnosis; a psychiatrist can diagnose it based on the patient’s history and symptoms. The differential diagnoses include major depression, anxiety disorders, ADHD, personality disorder, drug and alcohol misuse, schizophrenia, and consequences of trauma or brain injury.
The goal of treatment is to achieve as high as possible a level of psychosocial function and health-related quality of life. The treatment has two phases: the acute phase, focused on the management of acute mood episodes, and the maintenance phase, focused on preventing recurrences. Bipolar Disorder (Manic Depression) is highly recurrent, and sometimes medication needs to continue even if the patient feels well. The treatment of Bipolar Disorder (Manic Depression) includes mood stabilizers, antipsychotics, antidepressants, antianxiety medications, and psychotherapy. Drugs approved for treatment include Vraylar (cariprazine) and Latuda (lurasidone hydrochloride), among others.
Bipolar Disorder (Manic Depression) Market Players
Bipolar Disorder companies include:
- Allergan (AbbVie)
- Gedeon Richter
- Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
- Intra-Cellular Therapies
- NeuroRx
- Lundbeck
- Otsuka Pharmaceutical
- COMPASS Pathways
- Celon Pharma
- And Others.
Bipolar Disorder (Manic Depression) Epidemiology
The epidemiology section of the Bipolar Disorder (Manic Depression) market insight report provides historical and projected patient population data across the seven major markets (7MM), supported by key opinion leader perspectives that contextualize observed and anticipated trends. Relevant tables and graphs offer a clear view of prevalence patterns, with disclosed assumptions ensuring transparency in data interpretation. This section provides a robust understanding of disease burden across regions.
Key Findings:
- In the year 2020, the total diagnosed prevalent cases of Bipolar Disorder (Manic Depression) were 3,552,076 cases in the 7MM, which are expected to grow during the study period (2017–2030)
- The highest cases of Bipolar Disorder (Manic Depression) in the 7MM were in the United States, followed by Germany, Italy, the United Kingdom, France, Japan, and Spain in the year 2020
- In the United States, the total number of diagnosed prevalent cases of Bipolar Disorder (Manic Depression) was 2,401,287 cases in the year 2020, which are expected to grow during the study period (2017–2030)
- In the year 2020, the total diagnosed prevalent cases of Bipolar Disorder (Manic Depression) were 1,004,168 cases in EU-5, which are expected to grow during the study period (2017–2030)
- In Japan, the total number of diagnosed prevalent cases of Bipolar Disorder (Manic Depression) was 146,621 cases in the year 2020, which are expected to grow during the study period (2017–2030)
- The epidemiology of Bipolar Disorder (Manic Depression) is expected to evolve during the forecast period (2017–2030)
Bipolar Disorder (Manic Depression) Market Outlook
The Bipolar Disorder (Manic Depression) market trends point to continued expansion through the forecast period (2017–2030), driven by a rising prevalent population, growing awareness, and a robust pipeline of novel therapeutics. The therapeutic market of Bipolar Disorder (Manic Depression) in the seven major markets is expected to increase during the study period (2017–2030) with a CAGR of 11.9%. Among the 7MM, the highest market size of Bipolar Disorder (Manic Depression) is found in the United States, followed by Germany.
The total market size of Bipolar Disorder (Manic Depression) therapies in the United States is expected to increase with a CAGR of 11.6% during the study period (2017–2030). In EU-5 countries, the total market size is expected to increase with a CAGR of 13.4% during the same period. In Japan, the total market size is expected to increase with a CAGR of 11.5% during the study period (2017–2030).
Marketed Bipolar Disorder (Manic Depression) Drugs
- Vraylar/Cariprazine – Allergan (AbbVie)/Gedeon Richter
Vraylar is an oral capsule containing cariprazine as an active ingredient. It is approved in the US for schizophrenia, bipolar disorder, and Bipolar Disorder (Manic Depression). Cariprazine is a dopamine-serotonin partial agonist that binds to D3 dopamine, D2 dopamine, and 5HT2B serotonin receptors with high potency, and 5HT1A serotonin and 5HT2A serotonin receptors with moderate potency. In 2019, cariprazine was approved as a new second-generation antipsychotic (SGA) and joins quetiapine as the second SGA that is FDA-approved for both mania and depression. Vraylar was discovered and co-developed by Gedeon Richter Plc and is licensed by Allergan in the US.
- Latuda/Lurasidone Hydrochloride – Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
Latuda is an oral tablet containing lurasidone hydrochloride as an active ingredient. It is approved in the US for Bipolar Disorder (Manic Depression) in pediatric patients (10–17 years of age) and schizophrenic patients (adolescent and adult), given as monotherapy and adjunctive therapy in adult patients with Bipolar Disorder (Manic Depression). In the EU, it is approved for the treatment of schizophrenia, whereas in Japan, it is approved for both schizophrenia and bipolar disorder. Lurasidone is a benzothiazole-derivative, second-generation (atypical) antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A and 5-HT7 receptors. In 2013, lurasidone was approved as a monotherapy and adjunct to ongoing lithium or valproate for bipolar I depression.
Download the Bipolar Disorder (Manic Depression) market report for in-depth insights on pipeline and forecast
Emerging Bipolar Disorder (Manic Depression) Drugs
The Bipolar Disorder (Manic Depression) market size is expected to evolve significantly, supported by an active pipeline of emerging therapies addressing substantial unmet need. Key emerging candidates include lumateperone (ITI-007), NRX-100/NRX-101, SEP-4199, and brexpiprazole, among others, with active development programs targeting novel mechanisms, improved tolerability, and durable disease control.
- Lumateperone/ITI-007 – Intra-Cellular Therapies
Lumateperone (ITI-007) is an investigational, first-in-class small molecule that provides selective and simultaneous modulation of serotonin, dopamine, and glutamate – three neurotransmitter pathways implicated in severe mental illness. It is a potent serotonin 5-HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM), a dopamine D1 receptor-dependent indirect modulator of glutamate, and a serotonin reuptake inhibitor. Currently in Phase III clinical development for Bipolar Disorder (Manic Depression), the company submitted the sNDA to the US FDA in February 2021. If approved, this drug would be the first therapy indicated for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults.
- NRX-100/NRX-101 – NeuroRx
NeuroRx is developing a sequential therapy consisting of intravenous NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation, followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilization. NRX-101 is a proprietary, oral fixed-dose combination targeting the NMDA and 5-HT2a receptors. The molecule is currently under investigation in a Phase III clinical trial for rapid stabilization of acute suicidal ideation and behavior in patients with Bipolar Disorder (Manic Depression). In September 2017, the US FDA granted fast track designation to NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone) for Bipolar Disorder (Manic Depression) with suicidal ideation.
- SEP-4199 – Sunovion/Sumitomo Dainippon Pharma
SEP-4199 is a nonracemic ratio of amisulpride enantiomers with the potential to be the first benzamide treatment available in the US for mood disorders. It was designed to increase levels of serotonin 5-HT7 activity intended to enhance antidepressant efficacy and produce reduced levels of D2 receptor occupancy appropriate for the treatment of Bipolar Disorder (Manic Depression). The pharmacological effect of SEP-4199 is distinct from racemic amisulpride, which is approved in several countries outside the US for the treatment of schizophrenia and other psychiatric conditions.
- Brexpiprazole – Lundbeck/Otsuka Pharmaceutical
Brexpiprazole is an atypical antipsychotic agent with a partial dopamine receptor D2 agonist effect, discovered by Otsuka and co-developed by Otsuka and Lundbeck. It is a partial agonist at dopamine D2 receptors designed to have a similar binding affinity to dopamine and serotonin receptors. The efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors.
Bipolar Disorder (Manic Depression) Drugs Uptake
This section examines the sales uptake of potential Bipolar Disorder (Manic Depression) drugs launched or anticipated to launch between 2017 and 2030, estimating market penetration across countries and evaluating their impact within and across therapeutic classes and segments. It also addresses the financial and regulatory factors contributing to the probability of success of drugs in the Bipolar Disorder (Manic Depression) market.
Emerging therapies are analyzed on the basis of safety and efficacy in randomized clinical trials, order of market entry, broader market dynamics, and the degree to which they address unmet need within the Bipolar Disorder (Manic Depression) treatment landscape.
Discover the latest insights on Bipolar Disorder (Manic Depression) market trends and emerging therapies
Conclusion
The Bipolar Disorder (Manic Depression) market is poised for meaningful growth through 2030, supported by an increasing disease burden, heightened awareness, and continued advancements in therapeutic innovation. While antipsychotics remain the cornerstone of treatment, persistent unmet needs – particularly in managing depressive episodes, reducing relapse rates, and improving long-term tolerability – are driving the development of next-generation agents with novel mechanisms and improved efficacy. Promising pipeline candidates such as lumateperone (ITI-007), NRX-100/NRX-101, SEP-4199, and brexpiprazole have the potential to reshape the treatment landscape and enhance patient outcomes. As research progresses and access to innovative therapies expands, the Bipolar Disorder (Manic Depression) market is expected to witness significant transformation, creating new opportunities for stakeholders while addressing the long-term challenges associated with this debilitating condition.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
